
CapsoVision Inc (CV) Stock Forecast & Price Target
CapsoVision Inc (CV) Analyst Ratings
Bulls say
CapsoVision Inc. has demonstrated a positive financial trajectory, achieving nearly $12 million in revenue during 2024 from the CapsoCam Plus, which has been utilized in over 135,000 procedures, indicating strong market share gains. This consistent growth is exemplified by an annual revenue increase since the company's entry into the U.S. market, signifying ongoing demand for its innovative endoscopic video imaging technology. The promising future potential is further amplified by the company's development of the CapsoColon 3D, aimed at the large intestines, showcasing its commitment to expanding its product portfolio in the gastrointestinal imaging sector.
Bears say
CapsoVision Inc. faces significant challenges that could hinder its revenue growth and delay profitability, primarily due to resistance from physicians, hospitals, and patients regarding the retrieval of its capsule after ingestion. Additionally, potential disruptions in manufacturing, negative clinical outcomes, or product recalls could further undermine investor confidence and negatively impact revenue streams. The requirement for a CE mark may also restrict the sale of CapsoCam Plus, limiting the company’s growth potential, especially in new markets such as pediatric applications and fully digestible methods.
This aggregate rating is based on analysts' research of CapsoVision Inc and is not a guaranteed prediction by Public.com or investment advice.
CapsoVision Inc (CV) Analyst Forecast & Price Prediction
Start investing in CapsoVision Inc (CV)
Order type
Buy in
Order amount
Est. shares
0 shares